logo

Scynexis, Inc. (SCYX)



Trade SCYX now with
  Date
  Headline
1/8/2020 7:35:50 AM SCYNEXIS Announces Positive Results From The Second Interim Analysis Of Ongoing Phase 3 FURI Study
12/10/2019 6:24:22 AM SCYNEXIS Announces Pricing Of $35 Mln Public Offering Of Common Stock And Warrants
12/9/2019 4:06:06 PM SCYNEXIS Announces Launch Of Public Offering Of Common Stock And Warrants
11/12/2019 8:37:52 AM SCYNEXIS Q3 Net Loss $7.9 Mln Vs. Net Income $0.4 Mln Last Year
11/7/2019 8:13:16 AM SCYNEXIS Reports Results From First Phase 3 Registration Study Of Oral Ibrexafungerp In Vulvovaginal Candidiasis
9/18/2019 8:35:23 AM SCYNEXIS Completes Last-Patient In First Phase 3 Study Of Oral Ibrexafungerp For Treatment Of VVC
7/24/2019 9:02:27 AM SCYNEXIS Announces SPA Deal With FDA For Phase 3 Study Evaluating Oral Ibrexafungerp For Prevention Of Recurrent VVC
6/14/2019 8:32:20 AM SCYNEXIS Appoints Nkechi Azie As VP Of Clinical Development
5/30/2019 8:33:17 AM SCYNEXIS Completes Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration Of Ibrexafungerp
5/6/2019 8:32:36 AM SCYNEXIS Presents Data Further Supporting A Future NDA Submission Of Oral Ibrexafungerp For Vulvovaginal Candidiasis
4/3/2019 8:34:03 AM SCYNEXIS Reports Data Demonstrating Potential Use Of Ibrexafungerp As Agent To Address Multiple Serious Fungal Infection
2/28/2019 8:33:12 AM SCYNEXIS To Present Pre-clinical Data Supporting Prophylactic Use Of Ibrexafungerp At Superbugs And Superdrugs 2019
  
 
>